search
Compound Interest
Trends
- 1Insilico Medicine picks AI-designed obesity drug candidate ISM1354▼Insilico Medicine nominates AI-designed ISM1354 GIPR antagonist for obesity
Drug discovery company Insilico Medicine has nominated ISM1354, an AI-designed GIPR antagonist, as a preclinical drug candidate for the treatment of obesity. The compound was developed using the firm's artificial intelligence drug discovery platform, adding to a growing pipeline of AI-generated molecules advancing toward clinical development for metabolic disease.
- 2Micellar Formulation Boosts Xanthohumol Absorption in Human Trial●New Human Trial Shows Micellar Formulation Sharply Increases Xanthohumol Absorption
A new human trial has found that a micellar formulation sharply increases the absorption of xanthohumol, a compound derived from hops that has drawn interest for its potential health benefits. The findings suggest micellar delivery technology could make xanthohumol supplements significantly more bioavailable, a development likely to attract attention from supplement makers and nutrition researchers.
- 3Scientists search ocean microbes for new medicines▼The ocean as a medicine cabinet: Researchers search for useful microbes
Researchers are combing the ocean for microbes that could yield useful drugs, treating marine environments as a potential medicine cabinet. The work highlights growing interest in marine biodiversity as a source of antibiotics and other pharmaceutical compounds, as scientists explore organisms living in seas around the world for medically valuable properties.
- 4Vivian Tu warns of hidden tax squeezing household budgets▼Vivian Tu sounds the alarm on a hidden tax hitting your wallet
Personal finance educator Vivian Tu is warning consumers about what she calls a hidden tax that is quietly eroding household budgets. She says everyday costs are being pushed up in ways people do not notice on a receipt, and urges readers to watch where their money is leaking. Her advice: identify the expense and adjust spending before it compounds.
- 5
Personal finance advice on building wealth while earning a modest income is drawing large audiences. The guidance, circulating widely online, centres on saving consistently, investing early and letting compound growth do the heavy lifting rather than relying on a high paycheck. Many viewers are engaging with the idea that becoming a millionaire depends more on habits and time than on salary size.
- 6Study finds gallic acid slows prostate cancer progression▼Chinese Medical Journal study reveals gallic acid inhibits prostate cancer progression via the NF-κB/KLF7/L1CAM Axis
A study published in the Chinese Medical Journal reports that gallic acid, a natural plant compound, inhibits the progression of prostate cancer. Researchers say the effect works through the NF-κB/KLF7/L1CAM signalling axis, a molecular pathway involved in tumour growth and spread. The findings add to interest in plant-derived compounds as potential leads for prostate cancer therapy, though further research would be needed before clinical use.
- 7What happens in the brain when cannabis triggers anxiety●What happens in the brain when cannabis generates anxiety?
New coverage explores the neurological mechanism behind cannabis-induced anxiety, explaining why the drug can trigger paranoia and panic attacks in some users. The piece examines how cannabis compounds interact with brain regions that regulate fear and stress responses. The topic resonates as cannabis use expands through legalization and growing medical interest, while reports of adverse psychological reactions remain common.
- 8B7-33 Peptide Draws Attention in Biased Ligand Research▼B7-33 and the Expanding Frontier of Biased Ligand Research
B7-33, a relaxin-family peptide analogue studied for its biased signaling properties, is being highlighted as an example of how biased ligand research is expanding in pharmacology. Researchers interested in compounds that activate beneficial pathways while avoiding unwanted ones are citing B7-33 as a case study in designing drugs with fewer side effects. Discussion centers on its potential in fibrosis and cardiovascular research.
- 9EPA head visits Maine firm working to destroy PFAS chemicals▼Head of EPA visits Maine company developing technology to eliminate PFAS chemicals
The head of the Environmental Protection Agency visited a Maine company that is developing technology to eliminate PFAS, the so-called forever chemicals linked to health and environmental harm. The visit highlights federal interest in emerging methods for destroying the persistent compounds, which have contaminated water supplies across the US, including in Maine where PFAS spread through sludge-based fertiliser on farmland.